Prevention and Early Diagnosis of Uterine Cancer


Uterine cancer is the most common gynecologic cancer in the United States. Uterine cancer incidence and mortality rates have been increasing since 2007, with significant disparities persisting for decades. For example, Black women are twice as likely to die from uterine cancer than White women. 

ACOG is pleased to offer the free online course Prevention and Early Diagnosis of Uterine Cancer, which summarizes the relevant literature and existing recommendations to guide clinicians in the equitable prevention, early diagnosis, and special considerations of uterine cancer.

The learning objectives are to:

  • Identify risk factors for uterine cancer.
  • Summarize key health disparities in uterine cancer.
  • Identify effective methods for risk modification and early diagnosis of uterine cancer. 

Developed through a partnership with the Centers for Disease Control and Prevention (CDC), this course is available to women's health care practitioners including obstetrician-gynecologists, nurses, nurse practitioners, physician assistants, family physicians, medical students and residents, and allied health professionals.


ACCME Accreditation

The American College of Obstetricians and Gynecologists is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Category 1 Credit(s)TM 

The American College of Obstetricians and Gynecologists designates this enduring activity for a maximum of 7 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

College Cognate Credit(s)

The American College of Obstetricians and Gynecologists designates this enduring activity for a maximum of 7 Category 1 College Cognate Credit. The College has a reciprocity agreement with the AMA that allows AMA PRA Category 1 CreditsTM to be equivalent to College Cognate Credits. 

ANCCCA Accreditation

This nursing continuing professional development activity was approved by the Maryland Nurses Association, which is an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation (ANCCCA).

Evaluation Survey

Complete the course evaluation survey. Thank you for your feedback!

Additional Resources

Related journal articles from Obstetrics & Gynecology:

Conflict of Interest Disclosure

This project was supported by the Centers for Disease Control and Prevention (CDC) of the U.S. Department of Health and Human Services (HHS) under cooperative agreement number 6 NU38OT000287-03-03, which was awarded to the American College of Obstetricians and Gynecologists (ACOG).
All authors, contributors, reviewers, and staff have submitted a conflict of interest disclosure statement, and any potential conflicts have been considered and managed in accordance with ACOG’s Conflict of Interest Disclosure Policy. This policy, along with ACOG’s Privacy Policy, can be found on
Conflict of interest disclosure for faculty, planning committee, reviewers, and staff:

  • All authors received a one-time payment from ACOG for their participation in the development of uterine cancer educational materials. 
  • Nadeem R. Abu-Rustum, MD disclosed GRAIL and Stryker grants paid to his institution. He is the chair of the NCCN Clinical Practice Guidelines on Cervical, Vulva, and Uterine Cancer and is a member of the European Society of Gynaecological Oncology (ESGO) Endometrial Cancer Quality Indicators Working Group. 
  • Erica Bednar, MS, MPH, CGC’s position at the University of Texas MD Anderson Cancer Center is supported by philanthropic contributions to the MD Anderson Cancer Center Moon Shots Program ®. 
  • Rebecca Brooks, MD is a member of an AstraZeneca speakers’ bureau related to ovarian cancer, a past advisory board member and consultant for GSK and Merck & Co., Inc., and a past non-branded speaker for Clinical Care Options. 
  • David Chelmow, MD is a member of the United States Preventive Services Task Force (USPSTF), the president of ASCCP and immediate past president of the Council of University Chairs of Obstetrics and Gynecology, receives a stipend as the editor-in-chief of the Medscape Obstetrics and Gynecology Clinical Reference Book, and was on the American Board of Obstetrics and Gynecology Board of Directors during the evidence review and manuscript writing period. David Chelmow is a member of the United States Preventive Services Task Force (USPSTF). This material does not necessarily represent the views and policies of the USPSTF.
  • Amy L. Davis, DO, MS received renumeration by OptumRx for unrelated work.
  • Wenora Johnson is an employee of the Department of Energy, an ambassador and Clinical Trials Panel member at PCORI, a guidelines reviewer for the College of American Pathologists, a Technical Expert Panel member for the Centers for Medicare & Medicaid Services, a member of the National Coalition for Cancer Survivorship, a board member, Peer Navigator, and Research Advocate for FORCE, and part of the 2020/2021 Cancer Survivorship Project for the CDC.
  • Jeffrey Quinlan, MD is a member of the American Academy of Family Physicians (AAFP) Commission on the Health of the Public and Science and a Research Collaborator for DoctorLink (electronic decision support tool development).
  • Sangini Sheth, MD is a past consultant for Merck & Co., Inc., and a research study grant recipient (drug only: human papillomavirus [HPV] vaccine) from Merck & Co., Inc. She was paid costs of travel and meeting registration (paid directly) and received honoraria payment for an education course from the ASCCP. She also has research grants from the NIH and CDC for studies unrelated to the submitted work.
  • Brett Worly, MD is an unpaid speaker for AbbVie, Inc.

All other faculty, planning committee members, reviewers, and staff have no conflict of interest to disclose relative to the content of the presentation.